Peptidream (PPTDF) Drug Pipeline
21 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pd-32766D, Pd-32766T | Clear Cell Renal Cell Carcinoma | Phase I | Recruiting | A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma | Jun 17, 2026 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pd-32766D, Pd-32766T | Phase I | Clear Cell Renal Cell Carcinoma | Recruiting | A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma | Jun 17, 2026 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Peptidream (PPTDF) have in its pipeline
Peptidream PPTDF is currently developing the following drugs: Pd-32766D, Pd-32766T. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
